Miranda Molenaar, Author at ISA Therapeutics BV

About Miranda Molenaar

This author has not yet written his bio.
Meanwhile let's just say that we are proud Miranda Molenaar contributed with 30 entries.

Entries by Miranda Molenaar

Vaccine-Chemo Combo Shows Promise in Treating Advanced, HPV-Associated Cervical Cancer

30 Mar 2020

Blog by Arthur N. Brodsky, PhD, published on Cancerresearch.org on 27 March 2020. Click here to access the original article.

Just weeks after International Human Papilloma Virus (HPV) Awareness
Day, new results
from two long-time Cancer Research Institute (CRI) scientists highlighted the
promise of immunotherapy against HPV-associated cervical cancer.

In a phase 1/2 study, women with advanced, recurrent, or
metastatic cervical cancer were treated with the combination of an
HPV-targeting vaccine and standard-of-care chemotherapy. Of 72 evaluable
patients, 43 percent had their tumors shrink.

Led by Cornelis J.
M. Melief, M.D, Ph.D., and Sjoerd H. van der Burg, Ph.D.,
this clinical breakthrough was the latest fruit borne by the duo, both of
whom have been supported

ISA in the news: MedNous’ article on CervISA

27 Mar 2020

The platform for the medical research community MedNous wrote an article about our CervISA study:

Synthetic long peptides deliver response

A therapeutic cancer vaccine consisting of synthetic long peptides has delivered a meaningful survival benefit for cervical cancer patients when administered in combination with standard-of-care chemotherapy.

Sunday 22 March 2020A therapeutic cancer vaccine consisting of synthetic long peptides has delivered a meaningful survival benefit for cervical cancer patients when administered in combination with standard-of-care chemotherapy. The Phase 2 trial showed that the vaccine and carboplatin/paclitaxel chemotherapy were associated with prolonged survival.

The study was led by Cornelis Melief, chief scientific officer of ISA Pharmaceuticals

ISA Pharmaceuticals announces CervISA publication

19 Mar 2020

Synergy between Synthetic Long Peptides (SLP®) immunotherapeutics and standard chemotherapy in late stage cancer including meaningful survival improvements in SLP immune responders

Leiden, The Netherlands, 19 March 2020 — ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, announces publication of its phase 2, CervISA study in the peer-reviewed journal “Science Translational Medicine”. The paper titled ‘Strong vaccine responses during chemotherapy are associated with prolonged survival’ can be found here.

The CervISA study was an open label, phase 2 study in patients with late stage HPV16 positive cervical cancer. Seventy-seven patients were treated with ISA Pharma’s lead product, ISA101b, an HPV16-specific immunotherapeutic

ISA Pharmaceuticals Strengthens its Supervisory Board with the Addition of Dr. Markwin Velders

02 Sep 2019

– Seasoned biotech expert to support corporate development

Leiden, The Netherlands, September 02, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the addition of Dr. Markwin Velders to its Supervisory Board. Dr. Velders brings many years of experience in the biotech industry and currently holds a position as VP Operations and Managing Director at Kite Pharma EU, a leading company in the field of immuno-oncology and cell therapy.

“As we are entering the final stages of clinical development for our lead product ISA101b, we are happy to further

A One-Two Punch for HPV-16–positive Cancers?

30 Apr 2019

Video interview with ISA CSO Prof. Dr. Cornelis Melief at AACR 2019

18 Apr 2019

ecancer interviewed ISA’s Chief Science Officer Prof. Dr. Kees Melief on his views on cancer vaccines during the AACR annual meeting 2019 in Atlanta.

Prof. Melief discusses the favourability of cancer vaccines. Cancer vaccines can be easily applied to large numbers of patients and are low in cost. When combined with chemotherapy and immunotherapy they can have great benefit.

He also speaks about ISA’s latest study looking at the HPV-specific T-cell response after chemo-immunotherapy for advanced cervical cancer.

In Atlanta Prof. Melief received the AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019.

Link to the interview.

CRI Speaks with 2019 AACR-CRI Lloyd J. Old Award Recipient, Dr. Cornelis ‘Kees’ Melief

03 Apr 2019

Tuesday, April 2, 2019

Cornelis J. M. ‘Kees’ Melief, M.D., Ph.D., received the 2019 AACR-CRI Lloyd J. Old Award in Cancer Immunology presented by the American Association for Cancer Research (AACR) and Cancer Research Institute (CRI) during the 2019 AACR Annual Meeting.

Dr. Melief, a member of the CRI Scientific Advisory Council and CLIP Grant Review Committee, is being honored for his work on the development of effective immunotherapies for virus-induced tumors, including a novel vaccine strategy that uses synthetic long peptides (SLP) to target cancers associated with infection by the human papilloma virus (HPV). Arthur N. Brodsky, Ph D. interviewed

ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeting 2019

28 Mar 2019

– Results from Phase 2 cervical cancer trial with ISA101 selected for plenary oral presentation

Leiden, The Netherlands, March 28, 2019– ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will give an oral presentation at the upcoming AACR Annual Meeting 2019 in Atlanta, GA, USA, on March 31, 2019.

The presentation titled “A strong HPV-specific T-cell response after chemo-immunotherapy for advanced cervical cancer is associated with prolonged survival”is scheduled for Sunday, March 31, 2019, as part of the session “Predictive Biomarkers for Immunotherapy” (12:45-2:45pm, Marcus Auditorium- Bldg A-GWCC).

The data will outline the effects of vaccination

ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Cornelis Melief Receives AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019

19 Mar 2019

– Recognition for outstanding and innovative cancer research

Leiden, The
Netherlands, March 19, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology
company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis
Melief will receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019
from the American Association of Cancer Research (AACR) and the Cancer Research
Institute.

The AACR-CRI
Lloyd J. Old Award in Cancer Immunology recognizes an active scientist whose
outstanding and innovative research has had a major impact on the cancer field
and has the potential to stimulate new directions in cancer immunology.

The award was
established in honor of the late Lloyd J. Old, MD, who is

ISA’s AMPLIVANT® publication selected as noteworthy article in the January edition of JITC Digest

17 Jan 2019

The publication describing the mechanism of improved immunogenicity of conjugation of AMPLIVANT titled “Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication,” by Gijs G. Zom et al. was selected as one of four noteworthy articles in the January edition of the JITC Digest. It reports novel murine data demonstrating the enhanced immunological potency of the novel TLR2-ligand, AMPLIVANT, as an adjuvant in cancer immunotherapy (Zom et al. 2018).